SPDR S&P BIOTECH (XBI)
$81.04
3.36 (4.15%)
First-Mover Advantage Will Benefit Amarin Stock More Than You Think
There’s no reason Amarin stock won’t become a big success with Vascepa, especially with access to millions of patients.

Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:

Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:

Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:

Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$85.53
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
7.00M
Day's Range
$83.97 - $85.51
52-Week Range
$81.02 - $105.46
Dividend & Yield
$0.14 (0.17%)